Cardiff ECMC’s study combining AKT inhibitor AZD5363 with hormone therapy drug fulvestrant has now recruited its first patient, a radiographer from Barry in Wales.
TRACERx is being conducted at six sites, including five Experimental Cancer Medicine Centres: London-UCL, Leicester, Manchester, Aberdeen, Birmingham, and Cardiff.
Did you know support was available for professionals involved in the management of clinical trials data?
The National Lung Matrix Trial is a clinician-led collaborative study between the University of Birmingham, Cancer Research UK, Astra Zeneca and Pfizer.
The Experimental Cancer Medicine Centre initiative is jointly funded by Cancer Research UK, the National Institute for Health Research in England and the Departments of Health for Scotland, Wales and Northern Ireland.